Retinal biologics market revenue totaled USD 19.96 Billion in 2021. The global market is expected to reach USD 41.92 Billion by 2028, surging at a CAGR of 11.1% over the period of 2022 to 2028.
| Attribute | Details |
|---|---|
| Retinal Biologics Market Size (2022) | USD 22.25 Billion |
| Sales Forecast (2028) | USD 41.92 Billion |
| Global Market Growth Rate (2022 to 2028) | 11.1% CAGR |
| Share of Top 5 Players | 50% |
Retinal biologics accounted for 6.9% share of the global biologic therapeutics market in 2021.
| Particulars | Details |
|---|---|
| H1, 2021 | 11.08% |
| H1, 2022 Projected | 11.14% |
| H1, 2022 Outlook | 10.94% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 20 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 14 ↓ |
According to Future Market Insights' analysis, the global retinal biologics market expects to drop by 14 Basis Point Share (BPS) in H1-2022 as compared to H1-2021. Whereas in comparison to H1-2022 Projected value, the market during H1-2022 outlook period will show a dip of 20 BPS.
The availability of very few retinal biologics, their severe side effects, rigorous regulatory standards involved with obtaining biologics approvals, and the exorbitant cost of effective drugs and biologics are all contributing factors to the drop in BPS values.
The market will however witness a positive growth outlook over the forecast period, owed to the increasing intensive research activities for the production of novel biologics for novel disease therapeutics.
The key development in the market includes innovations in ocular drug delivery to the retina with the development of intravitreal drugs. The retinal biologics market is subject to macroeconomic and industrial factors in accordance to stringent regulatory standards and approval activities for biologics.
Rising Burden of Retinal Diseases to Boost Overall Market Growth
From 2013 to 2021, the global retinal biologics market registered significant gains, experiencing a CAGR worth 10.2%
Retinal biologics are bioengineered molecules that are implanted inside the eyes to heal chronic retinal diseases. Biologics are generally produced from living organisms such as microorganisms, or animal or plant cells. Some of the retinal biologics used for retinal diseases are Eylea, Lucentis, Humira, Macugen, and others.
Increased frequency of retinal diseases such as age-related macular degeneration around the world is driving the market expansion. According to WHO statistics, nearly 2.2 billion individuals worldwide suffer from near or distance vision impairment. As the prevalence of vision impairment rises, the need for effective therapeutic alternatives, such as retinal biologics, is rising as well.
Retinal biologics are a new class of medications that target specific markers in the patient's body to alleviate the symptoms of a variety of systemic or ocular disorders that present in the eye.
Considering these factors, the market is projected to witness high growth over the forecast period, registering an impressive CAGR of 11.1% to reach USD 41.92 Billion by 2028.
Rising R&D Activities in Retinal Gene Therapies to Fuel Market Expansion
The market will be driven by a strong focus on R&D connected with retinal gene therapies conducted by different institutes, biologics firms, and innovative product releases by prominent market participants in the form of biologics and implants. Efforts to develop a complementary therapeutic treatment will boost the market growth.
Market Growth Complemented by Increasing Burden of Retinal Diseases
Diabetic retinopathy has been a rising concern as the disease leads to vision loss among type I and type II adult diabetic patients. Diabetic macular edema also results from the consequences of diabetic retinopathy, which leads to the swelling of the macula. Moreover, increasing burden of other retinal diseases such as uveitis and orbital inflammation is another factor surging demand for retinal drugs and biologics.
Retinal gene therapy is a therapeutic approach wherein inherited defective genes are replaced by treatment with DNA or RNA. Retinal gene therapy is considered to be a significant approach as there occurs less contamination, and the viral vector can easily accommodate within the eyes.
Regulatory Obstructions Likely to Hinder Demand for Retinal Biologics
Limited availability of retinal biologics, hazardous biologic side effects, and limited access for retinal biologics and efficient treatments due to higher costs are restraining the market growth.
The market is being challenged by the side effects of retinal biologics, which include retinal tear, sickness, and eye pain. Governing authorities' strict regulatory compliances associated with biologics approval are impeding industry growth.
Ongoing Advancements in Biologics for Retinal Treatment
North America is expected to have a significant share in the global retinal biologics market. Continuous improvements in healthcare infrastructure, as well as an increase in the number of cases of retinal illnesses and favorable reimbursement policies, are expected to promote market expansion in the region.
Prominent presence of key manufacturers and increased healthcare spending are driving market growth in the region. Growing diabetes population is a major driver in the development of biologics for retinal treatment in North America.
Increased Prevalence of Diabetic Macular Edema to Augment Demand for Retinal Biologics
Diabetic retinopathy is a disease that affects people who have diabetes. Diabetic retinopathy is the major cause of new incidents of blindness in adults aged 20 to 74 years in the United States.
According to a new research study released by the Centers for Disease Control and Prevention, more than 100 million persons in the United States currently have diabetes or prediabetes.
In addition, researchers are working on innovative strategies to treat diabetic macular edema. As a result, rising R&D spending in the country as well as risk factors that contribute to disease development will have an impact on the retinal biologics market in the USA over the forecast period.
Rising Efforts for Development of Retinal Drugs to Drive Market Growth.
The market in China is expected to grow due to rapidly rising cases of uveitis, diabetic retinopathy, and macular degeneration. Diabetes is exacerbated by a shift in lifestyle and an increase in bad eating habits, as a result of these factors, the global market for retinal drugs and biologics is expected to expand significantly.
Along with increasing incidence of eye diseases, there are a growing number of research initiatives focused on retinal drugs. Furthermore, growing geriatric population, which is becoming a target patient pool for retinal biologics, will boost market growth in China.
VEGF-A Antagonists Most Preferred as They are Largely Tolerated & Give Instant Results to Eye Disorders.
VEGF-A antagonists are used to treat eye damage and enhance corneal wound healing. The global retinal biologics market is also expected to be fueled by the rising prevalence of other retinal illnesses such as orbital inflammation and uveitis.
VEGF-A antagonists are commonly given for the treatment of diabetic retinopathy and diabetic macular edema. In the case of non-infectious uveitis, it is seen to be the ideal alternative to typical suppressing treatments.
Many firms have focused on VEGF-A antagonists because they reduce angiogenesis. Manufacturers are investing in the development of retinal biologics in a similar field due to the widespread acceptance of VEGF-A antagonist therapy.
Increasing Adoption of Retinal Biologics for Macular Degeneration Treatment
Macular degeneration indication is expected to account 36.9% share of the retinal biologics market in 2022. Macular Degeneration is a vision loss condition that affects the macula.
Despite the availability of improved treatment alternatives, the global retinal biologics market is likely to benefit from the increased prevalence of macular degeneration. According to the American Macular Degeneration Foundation, the prevalence is higher than the combined rates of cataracts and glaucoma in over 10 million Americans (AMDF).
Because macular degeneration primarily affects adults aged 50 and over, the prevalence of MD continues to go up, despite improving treatment choices, as the population ages.
Several companies are entering into licensing and collaboration agreements to expand their products into various countries across the world to cater to unmet demand. Leading market players are concentrating their efforts on research & development to discover new medications and improve treatment options.
For instance,
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2028 |
| Historical Data Available for | 2013 to 2021 |
| Market Analysis | Value in USD Million |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia & Pacific; Middle East & Africa (MEA) |
| Key Countries Covered | USA, Canada, Mexico, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Nordic, Spain, Japan, China, India, Malaysia, Thailand, Australia, GCC Countries, South Africa, Turkey |
| Key Market Segments Covered | Drug Class, Indication, Distribution Channel, Region |
| Key Companies Profiled | Spark Therapeutics, Inc.; F. Hoffmann-La Roche Ltd.; Regeneron Pharmaceuticals, Inc.; AbbVie Inc.; Amgen Inc.; Novartis Pharma AG; MeiraGTx Limited; Oxurion NV; Santen Pharmaceutical Co., Ltd.; Bayer AG; Bausch Health Companies Inc.; Merck & Co., Inc. |
| Pricing | Available upon Request |
Table 01: Expenditure on Health, (% of GDP), by Country, 2013 - 2021
Table 02: Expenditure on Health, (% of GDP), by Country, 2013 - 2021
Table 03: North America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country
Table 04: North America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class
Table 05: North America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication
Table 06: North America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel
Table 07: Latin America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country
Table 08: Latin America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class
Table 09: Latin America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication
Table 10: Latin America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel
Table 11: Western Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country
Table 12: Western Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class
Table 13: Western Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication
Table 14: Western Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel
Table 15: Eastern Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country
Table 16: Eastern Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class
Table 17: Eastern Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication
Table 18: Eastern Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel
Table 19: Asia Pacific Excluding Japan Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country
Table 20: Asia Pacific Excluding Japan Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class
Table 21: Asia Pacific Excluding Japan Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication
Table 22: Asia Pacific Excluding Japan Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel
Table 23: Japan Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class
Table 24: Japan Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication
Table 25: Japan Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel
Table 26: Middle East and Africa Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country
Table 27: Middle East and Africa Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class
Table 28: Middle East and Africa Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication
Table 29: Middle East and Africa Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel
Table 30: Global Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Region
Table 31: Global Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class
Table 32: Global Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication
Table 33: Global Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel
Figure 1: Global Market Value (US$ Mn), by Regions
Figure 2: Global Market Value Share By Drug Class (2021)
Figure 3: Global Market Value Share By Indication (2021)
Figure 4: Global Market Value Share By Distributional Channel
Figure 5: Global Healthcare Expenditure in US$ Tn (2013–2021)
Figure 6: North America Market Size (US$ Mn) Analysis, 2013–2021
Figure 7: North America Market Size (US$ Mn) & Y-o-Y Growth (%),
Figure 8: North America Market Analysis by Country –2022 & 2028
Figure 9: North America Market Y-o-Y Growth Projections by Country, 2022 – 2028
Figure 10: North America Market Attractiveness Analysis by Country, 2022 – 2028
Figure 11: North America Market Analysis by Drug Class–2022 & 2028
Figure 12: North America Market Y-o-Y Growth Projections by Drug Class, 2022 – 2028
Figure 13: North America Market Attractiveness Analysis by Drug Class, 2022 – 2028
Figure 14: North America Market Analysis by Indication–2022 & 2028
Figure 15: North America Market Y-o-Y Growth Projections by Indication, 2022 – 2028
Figure 16: North America Market Attractiveness Analysis by Indication, 2022 – 2028
Figure 17: North America Market Analysis by Distribution Channel–2022 & 2028
Figure 18: North America Market Y-o-Y Growth Projections by Distribution Channel, 2022 – 2028
Figure 19: North America Market Attractiveness Analysis by Distribution Channel, 2022 – 2028
Figure 20: Latin America Market Size (US$ Mn) Analysis, 2013–2021
Figure 21: Latin America Market Size (US$ Mn) & Y-o-Y Growth (%),
Figure 22: Latin America Market Analysis by Country –2022 & 2028
Figure 23: Latin America Market Y-o-Y Growth Projections by Country, 2022 – 2028
Figure 24: Latin America Market Attractiveness Analysis by Country, 2022 – 2028
Figure 25: Latin America Market Analysis by Drug Class–2022 & 2028
Figure 26: Latin America Market Y-o-Y Growth Projections by Drug Class, 2022 – 2028
Figure 27: Latin America Market Attractiveness Analysis by Drug Class, 2022 – 2028
Figure 28: Latin America Market Analysis by Indication–2022 & 2028
Figure 29: Latin America Market Y-o-Y Growth Projections by Indication, 2022 – 2028
Figure 30: Latin America Market Attractiveness Analysis by Indication, 2022 – 2028
Figure 31: Latin America Market Analysis by Distribution Channel–2022 & 2028
Figure 32: Latin America Market Y-o-Y Growth Projections by Distribution Channel, 2022 – 2028
Figure 33: Latin America Market Attractiveness Analysis by Distribution Channel, 2022 – 2028
Figure 34: Western Europe Market Size (US$ Mn) Analysis, 2013–2021
Figure 35: Western Europe Market Size (US$ Mn) & Y-o-Y Growth (%),
Figure 36: Western Europe Market Analysis by Country –2022 & 2028
Figure 37: Western Europe Market Y-o-Y Growth Projections by Country, 2022 – 2028
Figure 38: Western Europe Market Attractiveness Analysis by Country, 2022 – 2028
Figure 39: Western Europe Market Analysis by Drug Class–2022 & 2028
Figure 40: Western Europe Market Y-o-Y Growth Projections by Drug Class, 2022 – 2028
Figure 41: Western Europe Market Attractiveness Analysis by Drug Class, 2022 – 2028
Figure 42: Western Europe Market Analysis by Indication–2022 & 2028
Figure 43: Western Europe Market Y-o-Y Growth Projections by Indication, 2022 – 2028
Figure 44: Western Europe Market Attractiveness Analysis by Indication, 2022 – 2028
Figure 45: Western Europe Market Analysis by Distribution Channel–2022 & 2028
Figure 46: Western Europe Market Y-o-Y Growth Projections by Distribution Channel, 2022 – 2028
Figure 47: Western Europe Market Attractiveness Analysis by Distribution Channel, 2022 – 2028
Figure 48: Eastern Europe Market Size (US$ Mn) Analysis, 2013–2021
Figure 49: Eastern Europe Market Size (US$ Mn) & Y-o-Y Growth (%),
Figure 50: Eastern Europe Market Analysis by Country –2022 & 2028
Figure 51: Eastern Europe Market Y-o-Y Growth Projections by Country, 2022 – 2028
Figure 52: Eastern Europe Market Attractiveness Analysis by Country, 2022 – 2028
Figure 53: Eastern Europe Market Analysis by Drug Class–2022 & 2028
Figure 54: Eastern Europe Market Y-o-Y Growth Projections by Drug Class, 2022 – 2028
Figure 55: Eastern Europe Market Attractiveness Analysis by Drug Class, 2022 – 2028
Figure 56: Eastern Europe Market Analysis by Indication–2022 & 2028
Figure 57: Eastern Europe Market Y-o-Y Growth Projections by Indication, 2022 – 2028
Figure 58: Eastern Europe Market Attractiveness Analysis by Indication, 2022 – 2028
Figure 59: Eastern Europe Market Analysis by Distribution Channel–2022 & 2028
Figure 60: Eastern Europe Market Y-o-Y Growth Projections by Distribution Channel, 2022 – 2028
Figure 61: Eastern Europe Market Attractiveness Analysis by Distribution Channel, 2022 – 2028
Figure 62: Asia Pacific Excluding Japan Market Size (US$ Mn) Analysis, 2013–2021
Figure 63: Asia Pacific Excluding Japan Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 64: Asia Pacific Excluding Japan Market Analysis by Country –2022 & 2028
Figure 65: Asia Pacific Excluding Japan Market Y-o-Y Growth Projections by Country, 2022 – 2028
Figure 66: Asia Pacific Excluding Japan Market Attractiveness Analysis by Country, 2022 – 2028
Figure 67: Asia Pacific Excluding Japan Market Analysis by Drug Class–2022 & 2028
Figure 68: Asia Pacific Excluding Japan Market Y-o-Y Growth Projections by Drug Class, 2022 – 2028
Figure 69: Asia Pacific Excluding Japan Market Attractiveness Analysis by Drug Class, 2022 – 2028
Figure 70: Asia Pacific Excluding Japan Market Analysis by Indication–2022 & 2028
Figure 71: Asia Pacific Excluding Japan Market Y-o-Y Growth Projections by Indication, 2022 – 2028
Figure 72: Asia Pacific Excluding Japan Market Attractiveness Analysis by Indication, 2022 – 2028
Figure 73: Asia Pacific Excluding Japan Market Analysis by Distribution Channel–2022 & 2028
Figure 74: Asia Pacific Excluding Japan Market Y-o-Y Growth Projections by Distribution Channel, 2022 – 2028
Figure 75: Asia Pacific Excluding Japan Market Attractiveness Analysis by Distribution Channel, 2022 – 2028
Figure 76: Japan Market Size (US$ Mn) Analysis, 2013–2021
Figure 77: Japan Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 78: Japan Market Analysis by Drug Class–2022 & 2028
Figure 79: Japan Market Y-o-Y Growth Projections by Drug Class, 2022 – 2028
Figure 80: Japan Market Attractiveness Analysis by Drug Class, 2022 – 2028
Figure 81: Japan Market Analysis by Indication–2022 & 2028
Figure 82: Japan Market Y-o-Y Growth Projections by Indication, 2022 – 2028
Figure 83: Japan Market Attractiveness Analysis by Indication, 2022 – 2028
Figure 84: Japan Market Analysis by Distribution Channel–2022 & 2028
Figure 85: Japan Market Y-o-Y Growth Projections by Distribution Channel, 2022 – 2028
Figure 86: Japan Market Attractiveness Analysis by Distribution Channel, 2022 – 2028
Figure 87: Middle East and Africa Market Size (US$ Mn) Analysis, 2013–2021
Figure 88: Middle East and Africa Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 89: Middle East and Africa Market Analysis by Country –2022 & 2028
Figure 90: Middle East and Africa Market Y-o-Y Growth Projections by Country, 2022 – 2028
Figure 91: Middle East and Africa Market Attractiveness Analysis by Country, 2022 – 2028
Figure 92: Middle East and Africa Market Analysis by Drug Class–2022 & 2028
Figure 93: Middle East and Africa Market Y-o-Y Growth Projections by Drug Class, 2022 – 2028
Figure 94: Middle East and Africa Market Attractiveness Analysis by Drug Class, 2022 – 2028
Figure 95: Middle East and Africa Market Analysis by Indication–2022 & 2028
Figure 96: Middle East and Africa Market Y-o-Y Growth Projections by Indication, 2022 – 2028
Figure 97: Middle East and Africa Market Attractiveness Analysis by Indication, 2022 – 2028
Figure 98: Middle East and Africa Market Analysis by Distribution Channel–2022 & 2028
Figure 99: Middle East and Africa Market Y-o-Y Growth Projections by Distribution Channel, 2022 – 2028
Figure 100: Middle East and Africa Market Attractiveness Analysis by Distribution Channel, 2022 – 2028
Figure 101: Global Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Region
Figure 102: Global Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class
Figure 103: Global Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication
Figure 104: Global Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel
Figure 105: Global Market Size (US$ Mn) Analysis, 2013–2021
Figure 106: Global Market Size (US$ Mn) & Y-o-Y Growth (%),
Figure 107: Global Market Absolute $ Opportunity, 2013–2028
The global retinal biologics market is estimated to exhibit a CAGR of 11.1% during the forecast period (2022 to 2028).
Macular degeneration accounts for 36.9% share of the retinal biologics market.
The global retinal biologics market is expected to reach a valuation of USD 41.92 Billion by 2028.
Increasing prevalence of diabetic eye diseases and significant R&D investments for developing biologics are key trends driving market growth.
Major players operating in the market include Spark Therapeutics, Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals, Inc., AbbVie Inc., and Amgen Inc.
Explore Similar Insights
Retinal Biologics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
